FDA clears first RF ablation treatment for osteoarthritis knee pain

Posted 15 Jul, 2017 [ssba]

The U.S. Food and Drug Administration (FDA) has approved the first and only radio frequency (RF) treatment to be cleared specifically to alleviate chronic knee pain due to osteoarthritis.

Marketed by Halyard Health as “Coolief,” the new procedure uses minimally-invasive needles and water-cooled electrodes that emit cooled RF energy to deactivate the sensory nerves responsible for sending pain signals to the brain.

“What we’re changing is the wiring of the knee — so we’re taking away the pain signal and interrupting it,” Dr. Amin Sandeep, a pain specialist at Rush University Medical Center in Chicago who performs the procedure, told NBC News. “We’re not changing the structure of the knee, but if we can get rid of the pain, she can be more functional,” Amin added, referring to a patient who said she felt significant relief after undergoing the procedure.

Please click the link below to read further:

https://www.meddeviceonline.com/doc/fda-clears-first-rf-ablation-treatment-for-osteoarthritis-knee-pain-0001

Have a question? Or would like to book in with us?

Get in Touch

Common Conditions
that we Treat Everyday

View All Conditions

Latest from the Blog

Posted 04 Oct, 2019

How To Prevent Headaches And Migraines During Pregnancy

Have you noticed an increase in your migraines and headaches since you became pregnant? Are you worried that they may be the result of some other underlying problem? Many pregnant women will suffer from migraines and headaches during their pregnancy. The increased hormone levels can even cause these headaches to be of...
Posted 07 Feb, 2019

Stellate Ganglion Block a Potential Lifesaver in Severe PTSD

Case reports are mounting of immediate, durable, and significant relief of severe refractory symptoms of posttraumatic stress disorder (PTSD), according to an anesthesiologist who has seen the benefits firsthand. Stellate ganglion blockade (SGB) “seems to significantly improve PTSD symptoms as well as significant...